Resolian, the CRO formerly known as Alliance, makes move into China with Denali acquisition
02 Nov 2023
AcquisitionOligonucleotide
Preview
Source: FierceBiotech
Resolian (formerly Alliance Pharma) continues to expand with the acquisition of bioanalytical CRO Denali Medpharma for an undisclosed price.
Resolian, which changed its name from Alliance Pharma earlier this year, has expanded its services with the acquisition of China-based bioanalytical CRO Denali Medpharma for an undisclosed price.
With the deal, Pennsylvania-based Resolian can claim bioanalysis labs in the U.S., U.K., Australia and China. Denali, which has 70 employees, is known for its work in the bioanalysis of oligonucleotide drugs and mRNA vaccines as well as liposomal drugs, ultra-sensitive assays for inhalation drugs and biomarker assays, Resolian said in a Nov. 1 press release.
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” Resolian CEO Patrick Bennett said in the release. Financial details of the acquisition weren’t disclosed.
The rebrand to Resolian came in May as part of the company’s integration of U.K.-based CRO Drug Development Solutions, which it acquired last year.
In late 2022, the CRO opened a new lab in Brisbane, Australia, to support preclinical and clinical testing. The 20,000-square-foot facility provides small- and large-molecule bioanalytical services.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.